Dekkun Corp: Series A $9.9M

Posted in I - Series A, Q - 1Q11, R - NORTH EAST, X - Bone Sub, X - Oncology, XX - MA

Dekkun (Cambridge, MA) a development-stage bioscience company focused on treatments of bone fractures and oncology. Participants include HealthCare Ventures.

Oct

2010

Anchor Therapeutics, Inc.: Series B $10M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - G-Protein, X - Oncology, XX - MA

Anchor Therapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on peptides to modulate G-protein coupled receptors in oncology, CV and inflammatory diseases, closed a $10M Series B financing. Participants include TVM Capital, HealthCare Ventures and Novartis Option Fund.

Oct

2010

DecImmune Therapeutics, Inc.: Series A $1M

Posted in I - Series A, Q - 3Q10, R - NORTH EAST, X - Autoimmune, X - Inflammation, XX - MA

DecImmune Therapeutics (Boston, MA) a development-stage biopharmaceutica focused on inflammation and autoimmunity, closed a $1M Series A financing. Participants include Astellas Venture Management, Amgen Ventures and HealthCare Ventures.

Aug

2010

TetraLogic Pharmaceuticals, Inc.: Series C $32M

Posted in I - Series C, Q - 3Q10, R - NORTH EAST, X - Apoptosis, X - Necrosis, XX - PA

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Aug

2010

Trevena, Inc.: Series B $35M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Cardiology, X - G-Protein, X - Pain, XX - PA

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Jul

2010

Stemgent, Inc.: Series B $5.6M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Reagent, X - Stem Cell, XX - MA

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

Jun

2010

FoldRx Pharmaceutials, Inc.: Series C $29M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Neuro Degenerative, X - Protein Folding, XX - MA

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

Apr

2010

GlobeImmune, Inc.: Series E $17.5M

Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Mar

2010

Promedior, Inc.: Series C $12M

Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Fibrosis, X - Inflammation, XX - PA

Promedior (Malvern, PA) a clinical-stage biopharmaceutical company focused on inflammation and fibrotic disease, closed a $12M Series C financing. Participants include Forbion Capital Partners, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners and Easton Capital.

Mar

2010

Seahorse Bioscience, Inc.: Series D $5M

Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Device (Bioenergetics), XX - MA

Seahorse Bioscience (Billerica, MA) commercial-stage providers of instruments for cellular bioenergetic measurements for better understanding of the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity, closed a $5M Series D financing. Participants include Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science [...]

Next Entries »

to top of page...